HSBC announces Zoetis (NYSE:ZTS) Price Target of $230
HSBC analyst Morten Herholdt initiates coverage on Zoetis (NYSE:ZTS) with a Buy rating and announces Price Target of $230.
HSBC announces Zoetis (NYSE:ZTS) Price Target of $230 Read Post »
Zoetis
As the world’s leading animal health company, Zoetis (NYSE:ZTS) is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide — from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees.
Stifel maintains Zoetis (NYSE:ZTS) $205 price target
Stifel analyst Jonathan Block reiterates Zoetis (NYSE:ZTS) with a Buy and maintains $205 price target.
Stifel maintains Zoetis (NYSE:ZTS) $205 price target Read Post »
Piper Sandler raises Zoetis (NYSE:ZTS) price target from $210 to $220
Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:ZTS) with a Overweight and raises the price target from $210 to $220.
Piper Sandler raises Zoetis (NYSE:ZTS) price target from $210 to $220 Read Post »
Goldman Sachs raises Zoetis (NYSE:ZTS) price target from $204 to $213
Goldman Sachs analyst Nathan Rich maintains Zoetis (NYSE:ZTS) with a Buy and raises the price target from $204 to $213.
Goldman Sachs raises Zoetis (NYSE:ZTS) price target from $204 to $213 Read Post »